- Home
- TLSI vs TLSA Comparison
TLSI vs TLSA Comparison
Compare TLSI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- TLSA
- Stock Information
- Founded
- TLSI 2010
- TLSA 2013
- Country
- TLSI United States
- TLSA United Kingdom
- Employees
- TLSI N/A
- TLSA N/A
- Industry
- TLSI Medical Specialities
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- TLSA Health Care
- Exchange
- TLSI Nasdaq
- TLSA Nasdaq
- Market Cap
- TLSI 204.0M
- TLSA 175.3M
- IPO Year
- TLSI N/A
- TLSA 2000
- Fundamental
- Price
- TLSI $5.43
- TLSA $1.59
- Analyst Decision
- TLSI Strong Buy
- TLSA
- Analyst Count
- TLSI 5
- TLSA 0
- Target Price
- TLSI $10.90
- TLSA N/A
- AVG Volume (30 Days)
- TLSI 146.8K
- TLSA 261.4K
- Earning Date
- TLSI 08-13-2025
- TLSA 07-11-2025
- Dividend Yield
- TLSI N/A
- TLSA N/A
- EPS Growth
- TLSI N/A
- TLSA N/A
- EPS
- TLSI N/A
- TLSA N/A
- Revenue
- TLSI $32,141,000.00
- TLSA N/A
- Revenue This Year
- TLSI $55.52
- TLSA N/A
- Revenue Next Year
- TLSI $54.76
- TLSA N/A
- P/E Ratio
- TLSI N/A
- TLSA N/A
- Revenue Growth
- TLSI 46.20
- TLSA N/A
- 52 Week Low
- TLSI $3.50
- TLSA $0.63
- 52 Week High
- TLSI $6.04
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- TLSI 50.01
- TLSA 53.42
- Support Level
- TLSI $5.18
- TLSA $1.54
- Resistance Level
- TLSI $5.65
- TLSA $1.81
- Average True Range (ATR)
- TLSI 0.35
- TLSA 0.12
- MACD
- TLSI -0.02
- TLSA 0.01
- Stochastic Oscillator
- TLSI 49.23
- TLSA 50.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.